Loading…
Contract development and manufacturing organization (CDMO) for pharmaceuticals, with plants in Taiwan and North America.
Contract development and manufacturing organization (CDMO) for pharmaceuticals, with plants in Taiwan and North America.
Paid by drugmakers under development and manufacturing contracts, so revenue rests on a limited number of multi-year client relationships. Its North American plants, bought from other drug companies, put capacity close to US customers.
In one line: A small-cap Catalent.
Moat: narrow (regulatory licence, switching costs, process know-how). FDA-approved plants and multi-year manufacturing contracts are costly for clients to re-qualify.
Headquarters: Taipei, Taiwan
Size Bora Pharmaceuticals (6472.TW) is a Taiwan Health Care company (Pharmaceuticals: Other) with a market value of $1.55B, the 197th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$399.50 on 6 Nov 2026.
Performance Over six months the shares fell 2.0%, against -4.8% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue fell 5.6% over the last twelve months (peer median +11.8%); the operating margin is 15.4% (peer median 14.8%).
Valuation It trades at 14.2× forward earnings against a peer median of 18.6× (7th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +60%, so the hurdle is -56 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.2 points above its cost of capital (5.0% WACC).
Next results Next results expected around 18 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$19.6B | NT$19.0B | NT$17.4B | NT$14.2B | NT$10.5B |
| Revenue growth | — | +9% | +23% | +35% | — |
| Gross profit | NT$7.57B | NT$7.66B | NT$7.63B | NT$6.91B | NT$2.86B |
| EBITDA | NT$4.09B | NT$4.23B | NT$4.56B | NT$5.85B | NT$2.25B |
| Net income | NT$1.55B | NT$2.98B | NT$3.85B | NT$3.03B | NT$1.39B |
| Free cash flow | NT$1.81B | NT$3.31B | NT$83.0M | NT$4.16B | NT$1.72B |
| Capital expenditure | NT$1.33B | NT$1.01B | NT$856M | NT$1.43B | NT$215M |
| Total debt | NT$21.8B | NT$18.2B | NT$19.0B | NT$5.01B | NT$7.60B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Bora Pharmaceuticals 6472.TW | $1.55B | -2% | -6% | 15% | 14.2× | 4.5% |
| Lonza LONN.SW | $55.4B | +39% | -11% | 25% | 36.1× | 15.0% |
| Siegfried SFZN.SW | $3.98B | -10% | +4% | 16% | 17.8× | n/a |
| PharmaEssentia 6446.TW | $15.8B | +118% | +64% | 38% | 39.2× | 29.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6472.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.0% | +0.5% | 6th lowest of 21 |
| 6-month return | -2.0% | -4.8% | 10th highest of 21 |
| Distance from 52-week high | -39.0% | -19.5% | 4th lowest of 21 |
| Revenue growth (TTM) | -5.6% | +11.8% | 5th lowest of 21 |
| Operating margin | 15.4% | 14.8% | 10th highest of 20 |
| Forward P/E | 14.2× | 18.6× | 7th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 4.5% | 0.1% | 7th most demanding of 17 |
| Growth delivered (Del g) | +60.2% | +8.7% | 2nd highest of 17 |
| Hurdle (Req g minus delivered) | -55.8 pp | -8.4 pp | least demanding of 17 |
| ROIC minus cost of capital | +2.2 pp | +2.7 pp | 8th lowest of 20 |
| EV / EBITDA | 16.4× | 15.9× | 5th most expensive of 10 |
| Net debt / EBITDA | 3.3× | -1.1× | most indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.55B | -2% | -6% | 15% | 14.2× | 4.5% | +60.2% |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.53B | +27% | -3% | 24% | 18.6× | -2.2% | +5.5% |
| Zhejiang Medicine 600216.SS | China | $1.61B | -23% | -6% | 7% | 11.3× | -6.7% | +3.9% |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.66B | -15% | -7% | 28% | n/a | -1.1% | +10.4% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.41B | +75% | +27% | 33% | 67.7× | n/a | n/a |
| Jamieson Wellness JWEL.TO | Canada | $1.35B | +35% | +15% | 15% | 21.2× | 11.0% | +15.3% |
| Cronos CRON.TO | Canada | $1.34B | +45% | +36% | -2% | 15.6× | 2.1% | +26.7% |
| Pharma Mar PHM.MC | Spain | $1.30B | -33% | +32% | 19% | 37.7× | 11.4% | -3.9% |
| BioGaia BIOG-B.ST | Sweden | $1.26B | -7% | +13% | 28% | 30.1× | 0.9% | +15.5% |
| Porton Pharma Solutions 300363.SZ | China | $1.92B | +14% | +6% | -2% | n/a | 5.3% | +10.4% |
| China Meheco 600056.SS | China | $2.00B | -14% | +2% | 3% | n/a | -0.8% | -2.1% |
| HBM 2142.HK | Hong Kong | $1.18B | -23% | +55% | 44% | 12.4× | 14.1% | +62.3% |
| Health and Happiness (H&H) International 1112.HK | Hong Kong | $2.05B | +70% | +24% | 16% | 12.6× | -3.0% | +4.4% |
| Granules India GRANULES.NS | India | $2.10B | +8% | +22% | 17% | 24.9× | 23.5% | +10.6% |
| Shandong Xinhua Pharmaceutical 0719.HK | Hong Kong | $1.09B | -11% | -1% | 4% | 6.8× | -2.0% | +7.1% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | China | $2.19B | -3% | -10% | 24% | 15.7× | -2.5% | +11.6% |
| Applied Nutrition APN.L | United Kingdom | $1.01B | +42% | +24% | n/a | 24.2× | n/a | n/a |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $999M | -16% | -14% | 8% | 193.0× | n/a | n/a |
| China Resources Double-Crane Pharmaceutical 600062.SS | China | $2.50B | -10% | -1% | 13% | 9.8× | -8.3% | +5.3% |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $952M | -35% | +30% | 15% | 9.7× | n/a | n/a |
| By-health 300146.SZ | China | $2.61B | -1% | +10% | 11% | 25.0× | 5.1% | +0.6% |